scholarly journals Interaction effects of diabetes and brain-derived neurotrophic factor on suicidal ideation in patients with acute coronary syndrome

2021 ◽  
Author(s):  
Wonsuk Choi ◽  
Ju-Wan Kim ◽  
Hee-Ju Kang ◽  
Hee Kyung Kim ◽  
Ho-Cheol Kang ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Suicidal Ideation ◽  
Neurotrophic Factor ◽  
Rating Scale ◽  
Brain Derived Neurotrophic Factor ◽  
Interaction Effects ◽  
Diabetic Patients ◽  
Val66met Polymorphism ◽  
Coronary Syndrome ◽  
Increased Risk

Abstract Background Acute coronary syndrome (ACS) is associated with an increased risk of suicide. Although both diabetes and the brain-derived neurotrophic factor (BDNF) pathway are closely related to ACS and suicide, the effects of these factors on suicidal behavior in ACS patients have not been assessed. The aim of this study was to investigate the individual and interaction effects of diabetes and BDNF-related markers, namely the serum BDNF (sBDNF) level and the BDNF Val66Met polymorphism, on suicidal ideation (SI) in ACS patients. Methods The presence of diabetes was ascertained, and sBDNF levels and the presence of the BDNF Val66Met polymorphism were measured in 969 patients within 2 weeks after an ACS episode. Among these patients, 711 were followed up at 1 year after the ACS episode. SI was evaluated using the relevant items of the Montgomery–Åsberg Depression Rating Scale at baseline (acute SI) and the 1-year follow-up (chronic SI). Results Significant individual effects of low sBDNF levels were found on acute SI. The presence of both diabetes and a low sBDNF level or the BDNF Met/Met genotype was associated with acute SI, with multivariate logistic regression analyses revealing significant interaction effects. The highest frequency of chronic SI was seen in diabetic patients with an sBDNF level in the lowest tertile or with the BDNF Met/Met genotype, although the interaction terms were not statistically significant. Conclusions Combining diabetes and BDNF-related markers, such as the sBDNF level and the BDNF Val66Met polymorphism, might provide a useful predictor of acute SI in patients with ACS.

Brain-derived neurotrophic factor is associated with coronary macrophage infiltrates in patients with acute coronary syndrome

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
R.A Montone ◽  
M Camilli ◽  
M Russo ◽  
M Del Buono ◽  
F Gurguglione ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Neurotrophic Factor ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
C Reactive Protein ◽  
St Segment Elevation ◽  
Protein Levels ◽  
Reactive Protein ◽  
Coronary Syndrome ◽  
St Segment

Abstract Background Brain-derived neurotrophic factor (BDNF) is a neurotrophine that plays a key role in the regulation of both central and peripheral nervous system. Moreover, BDNF is secreted in multiple tissues and exerts systemic, autocrine, and paracrine effects in the cardiovascular system. Of importance, BDNF expression was enhanced in macrophages and smooth muscle cells in atherosclerotic coronary arteries and may be involved in thrombus formation. Thus, BDNF has been suggested as an important link between inflammation and thrombosis, potentially involved in the pathogenesis of acute coronary syndrome (ACS). Purpose In our study we aimed at assessing serum levels of BDNF in patients with ACS, evaluating differences according to clinical presentation [ST-segment elevation myocardial infarction (STEMI) vs. Non-ST-segment elevation ACS (NSTE-ACS)]. Moreover, we assessed the presence of optical coherence (OCT)-defined macrophage infiltrates (MØI) in the culprit vessel of ACS patients and evaluated their relationship with BDNF levels. Methods ACS patients were prospectively selected. Blood samples were collected at admission and serum levels of BDNF were subsequently assessed. Presence of OCT-defined MØI along the culprit vessel was assessed. Results 166 ACS patients were enrolled [mean age 65.3±11.9 years, 125 (75.3%) male, 109 STEMI, 57 NSTE-ACS]. Serum levels of BDNF were higher among STEMI patients compared with NSTE-ACS [median (IQR) 2.48 pg/mL (1.54–3.34) vs. 2.12 pg/mL (1.34–2.47), p=0.007], while C-reactive protein levels did not differ between the two groups. OCT assessment was performed in 53 patients and MØI were detected in 27 patients. Of importance, patients with MØI in the culprit vessel had higher levels of BDNF compared with patients without MØI [median (IQR) 2.23 pg/mL (1.38–2.53) vs. 1.41 pg/mL (0.93–2.07), p=0.023], while C-reactive protein levels did not differ between the two groups. Of note, at multivariate regression analysis BDNF levels were independent predictor of MØI [OR: 2.20; 95% CI (1.02–4.74), p=0.043]. Conclusions Serum levels of BDNF may reliable identify the presence of local macrophage inflammatory infiltrates in patients with ACS. Moreover, BDNF levels are higher in patients with STEMI compared with NSTE-ACS. Taken together, these data suggest that BDNF may represent an interesting link between local inflammatory activation and enhanced thrombosis in ACS. BDNF serum levels Funding Acknowledgement Type of funding source: None

scholarly journals Association between plasma levels of BDNF and the antisuicidal effects of repeated ketamine infusions in depression with suicidal ideation

2020 ◽  
Vol 10 ◽  
pp. 204512532097379
Author(s):  
Wei Zheng ◽  
Yan-Ling Zhou ◽  
Cheng-Yu Wang ◽  
Xiao-Feng Lan ◽  
Bin Zhang ◽  
...  
Keyword(s):  
Suicidal Ideation ◽  
Correlation Analysis ◽  
Immunosorbent Assay ◽  
Neurotrophic Factor ◽  
Plasma Levels ◽  
Rating Scale ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Depressed Patients ◽  
Over Time

Background: This study is the first to examine the association between plasma levels of brain-derived neurotrophic factor (BDNF) and the antisuicidal effects of repeated ketamine infusions in depressed patients with suicidal ideation. Methods: Fifty-seven depressed patients with suicidal ideation received six ketamine infusions (0.5 mg/kg) during a 12 days period. Suicidality was measured with the Scale for Suicidal Ideations (SSI-part 1), item 10 of the Montgomery–Åsberg Depression Rating Scale (MADRS), and item 3 of the Hamilton Depression Rating Scale (HAMD) at baseline, 1 day after the first infusion (1 day), 1 day after the sixth infusion (13 days), and at 2 weeks after the last infusion (26 days). Plasma levels of BDNF were measured by enzyme-linked immunosorbent assay at baseline, 13 days, and 26 days. Results: Overall, 46 (80.7%) depressed patients with suicidal ideation had an antisuicidal response at 13 days. Despite a significant reduction in suicidal symptoms over time, no changes in plasma levels of BDNF were found after ketamine treatment when compared with baseline. Correlation analysis showed that no significant association was observed between the plasma levels of BDNF and the changes in the severity of suicidal symptoms as measured by SSI-part 1, item 10 of the MADRS, or item 3 of the HAMD at 1 day, 13 days, and 26 days (all p < 0.05). Conclusion: Our results indicated that plasma levels of BDNF may not serve as a biomarker for determining the antisuicidal effects of six ketamine infusions in depressed patients with suicidal ideation.

scholarly journals Emotional triggering and low socio-economic status as determinants of depression following acute coronary syndrome

2011 ◽  
Vol 41 (9) ◽  
pp. 1857-1866 ◽  
Author(s):  
A. Steptoe ◽  
G. J. Molloy ◽  
N. Messerly-Bürgy ◽  
A. Wikman ◽  
G. Randall ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Emotional Stress ◽  
Low Income ◽  
Rating Scale ◽  
Economic Status ◽  
Depression And Anxiety ◽  
Coronary Syndrome ◽  
Socio Economic Status ◽  
Acute Emotional Stress ◽  
Increased Risk

BackgroundThe determinants of depression following acute coronary syndrome (ACS) are poorly understood. Triggering of ACS by emotional stress and low socio-economic status (SES) are predictors of adverse outcomes. We therefore investigated whether emotional triggering and low SES predict depression and anxiety following ACS.MethodThis prospective observational clinical cohort study involved 298 patients with clinically verified ACS. Emotional stress was assessed for the 2 h before symptom onset and compared with the equivalent period 24 h earlier using case-crossover methods. SES was defined by household income and education. Depression was measured with the Beck Depression Inventory and the Hamilton Rating Scale for Depression and anxiety with the Hospital Anxiety and Depression Scale 3 weeks after ACS and again at 6 and 12 months. Age, gender, ethnicity, marital status, the Global Registry of Acute Coronary Events risk score, duration of hospital stay and history of depression were included as covariates.ResultsEmotional stress during the 2-h hazard period was associated with increased risk of ACS (odds ratio 1.88, 95% confidence interval 1.01–3.61). Both low income and emotional triggering predicted depression and anxiety at 3 weeks and 6/12 months independently of covariates. The two factors interacted, with the greatest depression and anxiety in lower income patients who experienced acute emotional stress. Education was not related to depression.ConclusionsPatients who experience acute emotional stress during their ACS and are lower SES as defined by current affluence and access to resources are particularly vulnerable to subsequent depression and anxiety.

scholarly journals Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study

2018 ◽  
Vol 9 (6) ◽  
pp. 589-598 ◽  
Author(s):  
Baris Gencer ◽  
Fabio Rigamonti ◽  
David Nanchen ◽  
Roland Klingenberg ◽  
Lorenz Räber ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Coronary Syndrome ◽  
Confidence Interval ◽  
Diabetic Patients ◽  
Coronary Syndrome ◽  
University Medicine ◽  
Fasting Hyperglycaemia ◽  
Increased Risk ◽  
Coronary Syndromes ◽  
One Year

Background: Controversy remains regarding the prevalence of hyperglycaemia in non-diabetic patients hospitalised with acute coronary syndrome and its prognostic value for long-term outcomes. Methods and results: We evaluated the prevalence of hyperglycaemia (defined as fasting glycaemia ⩾10 mmol/l) among patients with no known diabetes at the time of enrolment in the prospective Special Program University Medicine-Acute Coronary Syndromes cohort, as well as its impact on all-cause death, myocardial infarction, stroke and incidence of diabetes at one year. Among 3858 acute coronary syndrome patients enrolled between December 2009–December 2014, 709 (18.4%) had known diabetes, while 112 (3.6%) of non-diabetic patients had hyperglycaemia at admission. Compared with non-hyperglycaemic patients, hyperglycaemic individuals were more likely to present with ST-elevation myocardial infarction and acute heart failure. At discharge, hyperglycaemic patients were more frequently treated with glucose-lowering agents (8.9% vs 0.66%, p<0.001). At one-year, adjudicated all-cause death was significantly higher in non-diabetic patients presenting with hyperglycaemia compared with patients with no hyperglycaemia (5.4% vs 2.2%, p=0.041) and hyperglycaemia was a significant predictor of one-year mortality (adjusted hazard ratio 2.39, 95% confidence interval 1.03–5.56). Among patients with hyperglycaemia, 9.8% had developed diabetes at one-year, while the corresponding proportion among patients without hyperglycaemia was 1.8% ( p<0.001). In multivariate analysis, hyperglycaemia at presentation predicted the onset of treated diabetes at one-year (odds ratio 4.15, 95% confidence interval 1.59–10.86; p=0.004). Conclusion: Among non-diabetic patients hospitalised with acute coronary syndrome, a fasting hyperglycaemia of ⩾10 mmol/l predicted one-year mortality and was associated with a four-fold increased risk of developing diabetes at one year.

scholarly journals Insulin Receptor Substrate-1 Expression Is Increased in Circulating Leukocytes of Patients with Acute Coronary Syndrome

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Manuel F. Jiménez-Navarro ◽  
Héctor Bueno ◽  
Luis Alvarez-Sala ◽  
Noela Rodríguez-Losada ◽  
Vicente Andrés ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Insulin Receptor ◽  
Association Studies ◽  
Mononuclear Leukocytes ◽  
Diabetic Patients ◽  
Insulin Receptor Substrate ◽  
Genome Wide Association Studies ◽  
Mrna Levels ◽  
Coronary Syndrome ◽  
Increased Risk

The mechanisms underlying the increased risk of cardiovascular disease associated with diabetes mellitus (DM) are not fully defined. Insulin resistance in human metabolic syndrome patients is associated with decreased expression of the insulin receptor substrate-2- (Irs2-) AKT2 axis in mononuclear leukocytes (MLs). Moreover, acute coronary syndrome (ACS) has been linked through genome-wide association studies to the 2q36-q37.3 locus, which contains the Irs1 gene. Here, we investigated the expression of insulin-signaling pathway genes in MLs from patients with DM, ACS, and ACS plus DM. Quantitative real-time PCR expression studies showed no differences in the mRNA levels of Irs2, Akt2, and Akt1 among all patients. However, Irs1 mRNA expression was significantly increased in patients with ACS—diabetics and nondiabetics—compared with diabetic patients without ACS (P<.02 and P<.005, resp.). The present study reveals for the first time an association between increased Irs1 mRNA levels in MLs of patients with ACS which is not related to DM.

scholarly journals Antidiabetic Effect of Brain-Derived Neurotrophic Factor and Its Association with Inflammation in Type 2 Diabetes Mellitus

2017 ◽  
Vol 2017 ◽  
pp. 1-14 ◽  
Author(s):  
Ceren Eyileten ◽  
Agnieszka Kaplon-Cieslicka ◽  
Dagmara Mirowska-Guzel ◽  
Lukasz Malek ◽  
Marek Postula
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Neurotrophic Factor ◽  
Platelet Reactivity ◽  
Brain Derived Neurotrophic Factor ◽  
Diabetic Patients ◽  
Antidiabetic Effect ◽  
Coronary Syndrome

Brain-derived neurotrophic factor (BDNF) is a neurotrophin, which plays an important role in the central nervous system, and systemic or peripheral inflammatory conditions, such as acute coronary syndrome and type 2 diabetes mellitus (T2DM). BDNF is also expressed in several nonneuronal tissues, and platelets are the major source of peripheral BDNF. Here, we reviewed the potential role of BDNF in platelet reactivity in T2DM and its association with selected inflammatory and platelet activation mediators. Besides that, we focused on adipocytokines such as leptin, resistin, and adiponectin which are considered to take part in inflammation and both lipid and glucose metabolism in diabetic patients as previous studies showed the relation between adipocytokines and BDNF. We also reviewed the evidences of the antidiabetic effect of BDNF and the association with circulating inflammatory cytokines in T2DM.

Brain-derived neurotrophic factor in patients with acute coronary syndrome

2020 ◽  
Author(s):  
Rocco A. Montone ◽  
Massimiliano Camilli ◽  
Marco Giuseppe Del Buono ◽  
Michele Russo ◽  
Riccardo Rinaldi ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Coronary Syndrome

scholarly journals Association between the brain-derived neurotrophic factor Val66Met polymorphism and overweight/obesity in Mexican pediatric population

2017 ◽  
Author(s):  
José Darío Martínez-Ezquerro ◽  
Mario Enrique Rendón-Macías ◽  
Gerardo Zamora-Mendoza ◽  
Jacobo Serrano-Meneses ◽  
Beatriz Rosales-Rodríguez ◽  
...  
Keyword(s):  
Neurotrophic Factor ◽  
Pediatric Population ◽  
Brain Derived Neurotrophic Factor ◽  
Normal Weight ◽  
Val66met Polymorphism ◽  
Exact Test ◽  
Fisher's Exact Test ◽  
Increased Risk ◽  
Fisher’S Exact Test ◽  
Bdnf Rs6265

Background: The functional brain-derived neurotrophic factor (BDNF) rs6265 (G196A; Val66Met) single nucleotide polymorphism has been associated with eating disorders, BMI and obesity in distinct populations, both adult and pediatric, with contradictory results involving either Val or Met as the risk variant. Aim of the study: To determine the association between the BDNF Val66Met polymorphism and BMI in Mexican children and adolescents. Methods: BDNF Val66Met genotyping by restriction fragment length polymorphism and nutritional status characterized by their BMI-for-age z-scores (BAZ) from pediatric volunteers recruited in Mexico City (n=498) were analyzed by Fisher's exact test association analysis. Standardized residuals (R) were used to determine which genotype/allele had the major influence on the significant Fisher's exact test statistic. Odds ratios were analyzed to measure the magnitude and direction of the association between genotype and normal weight (≥ -2 SD < +1 SD) and overweight (≥ +1 SD, including obesity, Ow+Ob) status with 95% confidence intervals to estimate the precision of the effect as well as 95% credible intervals to obtain the most probable estimate. Results: Comparisons between GG (Val/Val), GA (Val/Met) and AA (Met/Met) genotypes or Met homozygotes vs. Val carriers (combination of GG and GA genotypes) showed significant differences (p=0.034 and p=0.037, respectively) between normal weight and the combined overweight and obese pediatric subjects. Our data showed that children/adolescents homozygous for the A allele have increased risk of overweight compared to the Val carriers (Bayesian OR= 4.2, 95% CI** [1.09-33.1]). Conclusion: This is the first report showing the significant association between the BDNF rs6265 AA (Met/Met) genotype and overweight/obesity in Mexican pediatric population.

Sign in / Sign up

Export Citation Format

Share Document